![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supporting Information)
14kB |
| Item Type: | Article |
|---|---|
| Title: | Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism |
| Creators Name: | Kim, H.J. and Aktas, O. and Patterson, K.R. and Korff, S. and Kunchok, A. and Bennett, J.L. and Weinshenker, B.G. and Paul, F. and Hartung, H.P. and Cimbora, D. and Smith, M.A. and Mittereder, N. and Rees, W.A. and She, D. and Cree, B.A.C. |
| Abstract: | Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes. |
| Keywords: | Aquaporin 4, Humanized Monoclonal Antibodies, IgG Receptors, Immunoglobulin G, Neuromyelitis Optica |
| Source: | Annals of Clinical and Translational Neurology |
| ISSN: | 2328-9503 |
| Publisher: | Wiley |
| Volume: | 10 |
| Number: | 12 |
| Page Range: | 2413-2420 |
| Date: | December 2023 |
| Official Publication: | https://doi.org/10.1002/acn3.51911 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
